Fig. 5

Expression of biomarkers in relation to nodal metastasis and survival in HNSCC. (a) IL6 expression is significantly higher in HNSCC samples compared to normal tissues, with increasing levels as the nodal metastasis status progresses from N0 to N3. (b) CXCL13 shows pronounced upregulation across all metastasis stages, with significant differences between normal tissues and stages N0–N3, as well as between N0 and N3. (c) PLAU exhibits progressively higher expression levels from N0 to N3, with significant differences observed between normal tissues and metastasis stages. (d–f) K–M survival analysis reveals that patients with higher expression of IL6, CXCL13, and PLAU have significantly lower survival probabilities, underscoring the prognostic value of these genes in HNSCC.